Resveratrol may have anti-chronic myelogenous leukemia activity. - GreenMedInfo Summary
AMPK- and p62/SQSTM1-dependent autophagy mediate resveratrol-induced cell death in chronic myelogenous leukemia.
Autophagy. 2010 Jul 21;6(5). Epub 2010 Jul 21. PMID: 20458181
INSERM U895, Nice, France; Université de Nice, LNCC (Equipe labellisée 2008-2010), INSERM U895, Team 2 Cell Death Differentiation and Cancer, Batiment ARCHIMED, Nice, France.
Resveratrol (RSV) is an attractive candidate for cancer therapy because of its ability to intervene at different levels in the AMPK/mTOR pathway. Indeed, RSV is unique in its capacity to inhibit both mTOR and S6 kinase and to activate AMPK. Our recent data reveals that RSV triggered autophagic cell death (ACD) in Chronic Myelogenous Leukemia (CML) cells, via both AMPK activation and JNK-mediated p62/SQSTM1 expression. Here we discuss how Resveratrol can mediate ACD in CML cells and the possibility of utilizing the AMPK/mTOR and JNK/p62 pathways via Resveratrol to combat CML and other hematopoietic malignancies.